€7.4bn ‘Just The Start’ For Global COVID-19 Drug & Vaccine Funding Project
Challenges Huge, Calls For IP On Coronavirus Tools To Be Pooled
It’s not enough just to develop new drugs and vaccines for COVID-19. These tools must be made available to all those who need them wherever they are; for this to happen, health systems will need to be strengthened, say the backers of an EU-led funding initiative. Industry says it has already brought considerable resources to the table and stresses that close international cooperation will be vital if the pandemic is to be tackled effectively.
You may also be interested in...
A global collaboration initiative launched by the World Health Organization is intended to foster the development of COVID-19 vaccines, medicines and diagnostics and to make sure they reach all those who need them.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.
With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.